



Media Release

12 September 2019

PHARMAXIS RECOGNISED AS A TOP INNOVATOR COMPANY IN ASIA PACIFIC

Pharmaceutical research company Pharmaxis (ASX: PXS) has welcomed its inclusion in a new report which ranks the company among the top 100 most innovative pharma companies in the APAC region.

The report prepared by Cortellis and entitled "*Pharmaceutical innovation in the APAC region*", studied a cohort of 929 companies (including multi-nationals) across 14 countries/regions that have or are developing innovative pharmaceutical products.

Pharmaxis was ranked 38 out of the 100 companies named as innovators in the small to medium- sized enterprises category. Amongst the 14 Australian companies included in the top 100, Pharmaxis was ranked second.

CEO Gary Phillips said, "I'm delighted but not surprised that Pharmaxis has been recognised in this report, the first of its kind. We have clearly met key indicators such as being able to demonstrate a strong pipeline and translate our R&D into actual drug candidates. Early stage partnering was also a measure studied for the report and Pharmaxis has made this a key business objective."

In 2015, Pharmaxis sold its anti-inflammatory drug candidate to Boehringer in a deal structured to deliver potential value in excess of \$A750 million.

The company's cystic fibrosis treatment Bronchitol® has been the subject of three large scale global clinical trials and is approved and marketed in Europe, Russia and Australia. The FDA is currently considering a submission to approve the product for US market. The Pharmaxis lung function test Aridol® was developed to help doctors diagnose and manage asthma and is available in Australia, major European countries, the United States and South Korea.

The Pharmaxis drug discovery team has moved four drugs into the clinic over the last five years. The company's pipeline is focused on anti-fibrotic agents to treat a variety of diseases through inhibiting the LOX and LOXL2 enzymes.

The Cortellis Report can be downloaded at:
http://discover.clarivate.com/APAC_PharmaRanking

#ends#

SOURCE: Pharmaxis Ltd, Sydney, Australia

CONTACT:

Media: Felicity Moffatt: T +61 418 677 701, E felicity.moffatt@pharmaxis.com.au

Investor relations: David McGarvey: T +61 438 880 106, E david.mcgarvey@pharmaxis.com.au

About Pharmaxis

Pharmaxis (ACN 082 811 630) is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval. Its product Bronchitol® for cystic fibrosis is marketed in Europe, Russia and Australia. Its product Aridol® for the assessment of asthma is sold in the United States, Europe, Australia and Asia. The company's development pipeline is centred on its expertise in amine oxidase chemistry and includes a series of Lysyl Oxidase Inhibitors under clinical development targeting fibrotic diseases of the heart, kidney, liver and lung. In May 2015, Boehringer Ingelheim acquired the Pharmaxis investigational drug PXS-4728A, a potent inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), to develop it for the treatment of the liver-related condition Non-alcoholic Steatohepatitis (NASH) and other inflammatory diseases. Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company's head office, manufacturing and research facilities are located in Sydney, Australia. For more information about Pharmaxis, please see www.pharmaxis.com.au

Forward-Looking Statements

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential of products and drug candidates. All forward-looking statements included in this media release are based upon information available to us as of the date hereof. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in partnering our LOXL2 program or any of the other products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.